GT Biopharma, Inc.

NasdaqCM:GTBP Stock Report

Market Cap: US$17.0m

GT Biopharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of GTBP?
Owner TypeNumber of SharesOwnership Percentage
Public Companies00%
Private Companies92,5330.257%
Institutions1,868,1035.18%
Individual Insiders2,501,6666.94%
General Public31,600,60287.6%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 1045.6%.

Top Shareholders

Top 25 shareholders own 11.83% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
5.9%
Robert Marzilli
2,128,089US$1.0m204%no data
1.25%
Vanguard Capital Management, LLC
451,875US$213.2k0%no data
0.82%
Geode Capital Management, LLC
294,459US$138.9k1,430%no data
0.68%
Michael Breen
243,539US$114.9k439%no data
0.63%
Vanguard Fiduciary Trust Company
225,938US$106.6k0%no data
0.33%
Rain Forest Partners LLC
120,518US$56.9k1,140%no data
0.26%
Bristol Capital Advisors LLC
94,798US$44.7k-89.3%55.57%
0.26%
Arax Advisory Partners, LLC
93,627US$44.2k0%no data
0.26%
Five Narrow Lane LP
92,533US$43.7k-29.8%no data
0.18%
Citadel Advisors LLC
66,165US$31.2k-18.1%no data
0.17%
Charles Casamento
62,500US$29.5k0%no data
0.14%
Alan Urban
50,000US$23.6k0%no data
0.14%
SeaCrest Wealth Management, LLC
50,000US$23.6k0%no data
0.13%
UBS Asset Management AG
45,970US$21.7k4,600,000%no data
0.088%
Two Sigma Securities, LLC
31,796US$15.0k154%no data
0.084%
LPL Financial LLC
30,382US$14.3k186%no data
0.07%
Intracoastal Capital LLC
25,248US$11.9k37.8%0.13%
0.065%
Invst, LLC
23,400US$11.0k0%no data
0.058%
Keel Point, LLC
20,768US$9.8k0%no data
0.056%
Cerity Partners LLC
20,023US$9.4k33.5%no data
0.055%
Integrated Wealth Concepts LLC
20,006US$9.4k0%no data
0.055%
Osaic Advisory Services, LLC
20,000US$9.4k0%no data
0.055%
Private Wealth Management Group LLC
20,000US$9.4k0%no data
0.049%
Martin Chopp
17,538US$8.3k17.1%no data
0.047%
Coston, McIsaac, and Partners Inc.
17,092US$8.1k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/04 01:32
End of Day Share Price 2026/07/02 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

GT Biopharma, Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Justin WalshB. Riley Securities, Inc.
Charles ButlerRoth Capital Partners
Jonathan AschoffRoth Capital Partners